Dr. Gomez Olivier's testosterone injection timing claims checked

What did @jmiguelgoa actually say?

The core argument here is about dosing frequency and receptor sensitivity. The creator distinguishes between different testosterone esters by their half-lives, then argues that injecting "more than 200 milligrams" in a single dose causes androgen receptor downregulation over time. The punchline, drawn from what sounds like a reference to Goldman and Hanguil's pharmacology text, is that trying to reduce injection frequency by stacking higher doses produces worse therapeutic outcomes, not better ones. "The optimal dose depends on your individual metabolism and milligrams," is roughly how they close it out.

Given the transcript quality, some of this reconstruction required interpretation. But the argument structure is coherent: low-frequency, high-dose injections are pharmacologically inferior to appropriately spaced, lower-dose protocols. That is a defensible position, and it maps onto real clinical debates in TRT management.

Does the science back this up?

Mostly, yes. The half-life figures cited are roughly accurate for known testosterone esters, and the receptor downregulation argument has biological support. Where it gets complicated is the "200 mg threshold" framing, which is presented as a clean cutoff when the reality is more individual.

Androgen receptor downregulation following supraphysiologic testosterone exposure is documented. Kvorning et al. (2006, Journal of Applied Physiology) showed that AR protein content in muscle decreased following sustained high-dose androgen exposure. Bhasin et al. (2001, Journal of Clinical Endocrinology and Metabolism) demonstrated dose-dependent effects of testosterone on body composition, but also noted that responses plateau and that HPG axis suppression scales with dose and duration. The creator's claim that exceeding a specific dose triggers receptor desensitization is directionally correct but oversimplified. Receptor behavior depends on tissue type, individual receptor density, and exposure duration, not a single milligram threshold.

The half-life breakdown the creator gives, roughly 2-3 days for propionate, 7-10 days for cypionate, and longer windows for decanoate, aligns with established pharmacokinetic data from Nieschlag and Behre's "Testosterone: Action, Deficiency, Substitution" (4th ed., 2012).

What did they get wrong (or right)?

They got the directional argument right. Piling milligrams into infrequent injections to avoid needles is a real problem in practice, and the pharmacokinetic rationale for frequent, lower-dose injections is sound. That deserves credit.

What they got wrong is presenting receptor downregulation as a binary event triggered by crossing a dose threshold. That is not how receptor biology works. Desensitization is a graded, tissue-specific, and time-dependent process. There is no universally validated cutoff at 200 mg or any other figure for clinical TRT purposes. Presenting one number as "the" threshold misleads viewers into thinking there is a precise pharmacological line they can manage themselves.

There is also a structural problem: the creator appears to be advising viewers on how to interpret their own dosing relative to physiological markers. Without knowing a patient's baseline testosterone levels, SHBG, hematocrit, and clinical symptoms, no dose recommendation is appropriate from a video. The framing that "coaches" who push high doses are harming patients is fair commentary, but it does not substitute for individualized clinical evaluation.

What should you actually know?

Testosterone ester choice and injection frequency are clinically meaningful decisions, not just convenience preferences. Testosterone cypionate, the most commonly prescribed ester in the US, has a half-life of approximately 8 days (Behre et al., 1999, European Journal of Endocrinology), which supports weekly or twice-weekly dosing to maintain stable serum levels and avoid the peaks and troughs that correlate with mood instability, erythrocytosis risk, and symptom fluctuation.

The HPG axis suppression point the creator raises is well-established. Exogenous testosterone suppresses LH and FSH through negative feedback, and this suppression is dose-dependent (Coviello et al., 2005, Journal of Clinical Endocrinology and Metabolism). Higher doses do not produce proportionally better outcomes for most hypogonadal patients. The Endocrine Society's 2018 clinical practice guidelines recommend targeting mid-normal physiologic testosterone ranges, not supraphysiologic levels, precisely because the risk-benefit profile shifts unfavorably above that range.

If you are on TRT or considering it, the practical takeaway is that more testosterone is not automatically better, and injecting large infrequent doses to minimize needle frequency is a tradeoff with real pharmacokinetic consequences. How your protocol is structured should be determined by lab work and clinical supervision, not a TikTok half-life chart.